Yes, very sensible SC. Let us all just keep our feet on
the ground.
As long as everyone has examined the Gid trial
procedures to form a balanced opinion.
IMO we should be watching the Gid Phase 3
progress with as much interest as our own
PAR Phase 3.
Mozz, maybe MSB and OCC shareholders would
be disappointed to hear you say that. They think
that the adoption of widespread stemcell therapies
is very close.
research reports and media, page-746
-
- There are more pages in this discussion • 3,610 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.0¢ |
Change
-0.020(8.00%) |
Mkt cap ! $80.45M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 23.0¢ | $235.8K | 980.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 100000 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 6521 | 2 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |